SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.252
AS - Asia 1.785
EU - Europa 1.387
SA - Sud America 289
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 41
OC - Oceania 7
Totale 8.867
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.130
SG - Singapore 634
GB - Regno Unito 362
CN - Cina 300
VN - Vietnam 232
IT - Italia 231
HK - Hong Kong 220
BR - Brasile 219
FI - Finlandia 185
DE - Germania 168
BD - Bangladesh 140
SE - Svezia 139
RU - Federazione Russa 79
FR - Francia 75
TR - Turchia 67
CA - Canada 48
ID - Indonesia 39
IN - India 32
BG - Bulgaria 31
JP - Giappone 25
AR - Argentina 24
UA - Ucraina 19
IQ - Iraq 18
NL - Olanda 18
IE - Irlanda 16
VE - Venezuela 14
MX - Messico 11
JM - Giamaica 10
PK - Pakistan 10
ZA - Sudafrica 10
CO - Colombia 9
EG - Egitto 9
AT - Austria 8
KR - Corea 8
TT - Trinidad e Tobago 8
BE - Belgio 7
CR - Costa Rica 7
CW - ???statistics.table.value.countryCode.CW??? 7
SA - Arabia Saudita 7
MY - Malesia 6
CH - Svizzera 5
CL - Cile 5
EC - Ecuador 5
GT - Guatemala 5
HN - Honduras 5
JO - Giordania 5
MA - Marocco 5
PE - Perù 5
PH - Filippine 5
PR - Porto Rico 5
RO - Romania 5
UZ - Uzbekistan 5
AU - Australia 4
AZ - Azerbaigian 4
BZ - Belize 4
DK - Danimarca 4
EE - Estonia 4
IL - Israele 4
LT - Lituania 4
LU - Lussemburgo 4
NI - Nicaragua 4
NO - Norvegia 4
NP - Nepal 4
OM - Oman 4
PY - Paraguay 4
SV - El Salvador 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
GP - Guadalupe 3
KE - Kenya 3
MQ - Martinica 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
ES - Italia 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
PL - Polonia 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DM - Dominica 1
DZ - Algeria 1
GA - Gabon 1
IR - Iran 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
Totale 8.758
Salva come PNG Salva come JPEG
Città #
Fairfield 712
Ashburn 606
Santa Clara 423
Singapore 407
Seattle 305
Woodbridge 292
Chandler 251
Houston 251
Wilmington 219
Cambridge 218
Hong Kong 216
Southend 210
San Jose 195
Helsinki 174
Council Bluffs 162
Dearborn 117
Nyköping 106
London 99
Ann Arbor 74
New York 69
Beijing 61
Izmir 58
Ho Chi Minh City 55
Hanoi 50
San Diego 47
Dong Ket 44
Boardman 43
Los Angeles 40
The Dalles 40
Lauterbourg 38
Jakarta 34
Chicago 32
Munich 32
Milan 31
Phoenix 31
Princeton 31
Sofia 31
Bremen 30
Eugene 30
Shanghai 26
Orem 25
São Paulo 24
Tokyo 22
Modena 20
Buffalo 19
Dallas 18
North Bergen 15
Redondo Beach 15
Dublin 14
Montreal 12
Atlanta 11
Jacksonville 11
Denver 10
Falkenstein 10
Columbus 9
Frankfurt am Main 9
Saint Augustine 9
Turku 9
Cairo 8
Hefei 8
Naples 8
Portsmouth 8
Salt Lake City 8
Brooklyn 7
Chennai 7
Da Nang 7
Haiphong 7
Kunming 7
Miano 7
Moscow 7
Norwalk 7
Rio de Janeiro 7
Seoul 7
Toronto 7
Willemstad 7
Baghdad 6
Charlotte 6
Curitiba 6
Guangzhou 6
Hanover 6
Rome 6
Salvador 6
San Francisco 6
Turin 6
Amsterdam 5
Blainville 5
Brussels 5
Criciúma 5
Jieyang 5
Kingston 5
Mumbai 5
Vancouver 5
Amman 4
Baku 4
Belize City 4
Catania 4
Dhaka 4
Düsseldorf 4
Edinburgh 4
Hounslow 4
Totale 6.402
Salva come PNG Salva come JPEG
Nome #
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 380
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 349
Immunotherapy for colorectal cancer: where are we heading? 347
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 334
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 331
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 329
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 323
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 316
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 311
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 307
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 305
Immunotherapeutic approaches for hepatocellular carcinoma 290
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 288
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 286
The Italian Rare Pancreatic Exocrine Cancer Initiative 285
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 279
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 271
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 266
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 265
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 262
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 258
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 257
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 256
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 254
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 251
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 249
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 249
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 240
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 229
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 200
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 162
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 138
Totale 8.867
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022467 0 0 0 0 15 45 13 49 62 76 129 78
2022/2023727 87 80 40 59 105 80 16 75 86 9 46 44
2023/2024288 9 16 10 45 65 2 33 40 3 7 8 50
2024/20251.399 39 24 5 116 286 229 141 84 190 45 75 165
2025/20262.254 125 47 97 179 366 159 310 83 227 212 246 203
2026/2027673 76 143 151 300 3 0 0 0 0 0 0 0
Totale 8.867